Glycopyrrolate

• CAT Number: A000023
• CAS Number: 596-51-0
• Molecular Formula: C19H28BrNO3
• Molecular Weight: 398.3
• Purity: ≥95%
• Synonyms: Glycopyrrolate bromide, Glycopyrronium bromide, Robinul, Gastrodyn
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• InChI: 1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1
• InChIKey: VPNYRYCIDCJBOM-UHFFFAOYSA-M
• SMILES: O=C(OC1CC[N+](C)(C)C1)C(O)(C2=CC=CC=C2)C3CCCC3.[Br-]

Glycopyrrolate is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has no to few central effects. Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. A muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. A synthetic quaternary amine, it is available in oral and intravenous forms. It was developed by Sosei and licensed to Novartis in 2005.

Reference

1: Liu Y, Yu L, Zhang H, Chen D. Dispersive micro-solid-phase extraction combined
with online preconcentration by capillary electrophoresis for the determination
of glycopyrrolate stereoisomers in rat plasma. J Sep Sci. 2017 Oct 28. doi:
10.1002/jssc.201700753. [Epub ahead of print] PubMed PMID: 29080329.
2: Salla KM, Tuns CI, Bennett RC, Raekallio MR, Scheinin M, Kuusela E, Vainio OM.
Cardiovascular effects of premedication with medetomidine alone and in
combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with
isoflurane. Am J Vet Res. 2017 Nov;78(11):1245-1254. doi:
10.2460/ajvr.78.11.1245. PubMed PMID: 29076369.
3: [French comment on article Safety and efficacy of glycopyrrolate as a
premedication for endoscopic submucosal dissection: a randomized, double-blind,
placebo-controlled study]. Endoscopy. 2017 Oct;49(10):1024-1025. doi:
10.1055/s-0043-118322. Epub 2017 Sep 27. French. PubMed PMID: 28954323.
4: Pong CK. Glycopyrrolate (Seebri Neohaler) for Maintenance Therapy in Patients
with COPD. Am Fam Physician. 2017 Sep 15;96(6):395-398. PubMed PMID: 28925636.
5: Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of
glycopyrrolate/eFlow(®) CS in moderate-to-very-severe COPD: Results from the
Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5
randomized study. Respir Med. 2017 Aug 24. pii: S0954-6111(17)30290-1. doi:
10.1016/j.rmed.2017.08.020. [Epub ahead of print] PubMed PMID: 28919143.
6: Ferguson GT, Taylor AF, Thach C, Wang Q, Schubert-Tennigkeit AA, Patalano F,
Banerji D. Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate
Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.
Chronic Obstr Pulm Dis. 2016 Aug 18;3(4):716-728. doi:
10.15326/jcopdf.3.4.2016.0131. PubMed PMID: 28848898; PubMed Central PMCID:
PMC5556955.
7: Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT. Efficacy
and safety of glycopyrrolate/eFlow(®) CS (nebulized glycopyrrolate) in
moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive
lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled
trials. Respir Med. 2017 Jul 19. pii: S0954-6111(17)30210-X. doi:
10.1016/j.rmed.2017.07.011. [Epub ahead of print] PubMed PMID: 28838685.